Evidence map›Paper›PMID 27374313›Full record

ArticleEBioMedicine2016

Activation of PPARγ by a Natural Flavonoid Modulator, Apigenin Ameliorates Obesity-Related Inflammation Via Regulation of Macrophage Polarization.

Xiujing Feng, Dan Weng, Feifei Zhou, Young D Owen, Haohan Qin, Jingfa Zhao, WenYu, Yahong Huang, Jiajia Chen, Haijian Fu and 5 more

Open access · goldAbstract read
In one paragraph

Article in EBioMedicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 161 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Classification and regulatory interactions of key transcription factors in COVID-19.Frontiers in cellular and infection microbiology · 2025
    Review

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Xiujing FengState Key Laboratory of Pharmaceutical Biotechnology, School of life Sciences, Nanjing University, Nanjing 210046, China.
Dan WengCenter for Molecular Metabolism, Nanjing University of Science and Technology, Nanjing 210094, China.
Feifei ZhouState Key Laboratory of Pharmaceutical Biotechnology, School of life Sciences, Nanjing University, Nanjing 210046, China.
Young D OwenGraduate Medical Education, Virginia Mason Medical Center, Seattle, WA 98101, USA.
Haohan QinState Key Laboratory of Pharmaceutical Biotechnology, School of life Sciences, Nanjing University, Nanjing 210046, China.
Jingfa ZhaoState Key Laboratory of Pharmaceutical Biotechnology, School of life Sciences, Nanjing University, Nanjing 210046, China.
WenYuState Key Laboratory of Pharmaceutical Biotechnology, School of life Sciences, Nanjing University, Nanjing 210046, China.
Yahong HuangState Key Laboratory of Pharmaceutical Biotechnology, School of life Sciences, Nanjing University, Nanjing 210046, China.
Jiajia ChenState Key Laboratory of Pharmaceutical Biotechnology, School of life Sciences, Nanjing University, Nanjing 210046, China.
Haijian FuKey Lab of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210046, China.
Nanfei YangState Key Laboratory of Pharmaceutical Biotechnology, School of life Sciences, Nanjing University, Nanjing 210046, China.
Dianhua ChenState Key Laboratory of Pharmaceutical Biotechnology, School of life Sciences, Nanjing University, Nanjing 210046, China.
Jianxin LiKey Lab of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210046, China.
Renxiang TanState Key Laboratory of Pharmaceutical Biotechnology, School of life Sciences, Nanjing University, Nanjing 210046, China.
Pingping ShenState Key Laboratory of Pharmaceutical Biotechnology, School of life Sciences, Nanjing University, Nanjing 210046, China; MOE Key Laboratory of Model Animal for Disease Study, Model Animal Research Center, Nanjing Biomedical Research Institute, Nanjing Biomedical Research Institute, Nanjing University, Nanjing 210046, China. Electronic address: ppshen@nju.edu.cn.
Nanjing University · CNNanjing University of Science and Technology · CNVirginia Mason Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PPARγ has emerged as a master regulator of macrophage polarization and is the molecular target of the thiazolidinedione drugs. Here we show that apigenin binds and activates PPARγ by acting as a modulator. Activation of PPARγ by apigenin blocks p65 translocation into nuclei through inhibition of p65/PPARγ complex translocation into nuclei, thereby decreasing NF-κB activation and favoringM2 macrophage polarization. In HFD and ob/ob mice, apigenin significantly reverses M1 macrophage into M2 and reduces the infiltration of inflammatory cells in liver and adipose tissues, as well as decreases the levels of pro-inflammatory cytokines, thereby alleviating inflammation. Strikingly, apigenin reduces liver and muscular steatosis, decreases the levels of ALT, AST, TC and TG, improving glucose resistance obviously. Unlike rosiglitazone, apigenin does not cause significant weight gain, osteoporosis et al. Our findings identify apigenin as a modulator of PPARγ and a potential lead compound for treatment of metabolic disorders.

Indexed as

Adipose TissueAnimalsApigeninBiomarkersCell LineCytokinesDisease Models, AnimalImmunophenotypingInflammationMacrophage ActivationMacrophagesMacrophages, PeritonealMaleMetabolic SyndromeMiceNF-kappa BApigeninBiomarkersCytokinesNF-kappa BPPAR gammaThiazolidinedionesApigeninMacrophage polarizationNF-κBObesity-related inflammationPPARγ

Identifiers

PMID27374313
PMCPMC4972579
OpenAlexW2432227722

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.